ALGS (Aligos Therapeutics) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $6.63
GF Value $2.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics NonCurrent Deferred Liabilities?

Aligos Therapeutics ALGS -2.22% 37 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aligos Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Aligos Therapeutics NonCurrent Deferred Liabilities Related Terms

Aligos Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics NonCurrent Deferred Liabilities Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.23 0.00 0.00 0.00

Aligos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALGS
37GF Score
Aligos Therapeutics Inc ALGS
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Aligos Therapeutics (ALGS) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' NonCurrent Deferred Liabilities too high?
Aligos Therapeutics' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' NonCurrent Deferred Liabilities compare to SNTI and NTRB?
Aligos Therapeutics' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0.00 Mil. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • NonCurrent Deferred Liabilities: $0.00 Mil
  • GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price
$2.78
GF Value